Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Royal Philips (Koninklijke Philips N.V., NYSE: PHG) is a health technology company whose news flow centers on diagnostic imaging, ultrasound, image-guided therapy, monitoring, enterprise informatics and personal health. Company announcements frequently highlight AI-enabled systems, new product launches and strategic portfolio moves, giving investors and observers insight into how Philips develops and positions its health technology offerings.
Recent Philips news has featured AI-powered innovations in image-guided therapy and diagnostic imaging, such as LumiGuide 3D Device Guidance for light-based navigation during minimally invasive procedures, DeviceGuide for AI-assisted tracking of heart valve repair devices, and Verida, a detector-based spectral CT system with AI integrated across the imaging chain. The company also reports advances in MRI through its BlueSeal Horizon 3.0T platform and extended partnerships in neuroimaging, such as the integration of Cortechs.ai quantitative analytics into Philips MR workflows.
News items also cover enterprise informatics and cloud-based solutions, including the launch of Philips Management 15, a web-based diagnostic viewer that delivers full radiology capabilities through a browser and interfaces with AI tools and interactive reporting. In addition, Philips communicates on long-term partnerships with health systems, monitoring agreements and large-scale deployments of its Azurion image-guided therapy systems.
Corporate and portfolio developments appear regularly in the news stream. Examples include the agreement to acquire SpectraWAVE Inc. to expand intravascular imaging and physiology solutions, and the completed carve-out of the Philips Emergency Care business, which now operates as Heartstream under a Philips brand license. Earnings-related releases and Form 6-K summaries provide context on comparable order intake, sales trends, margins, productivity programs and outlook.
Investors and healthcare professionals following PHG news can use this page to track product introductions, AI and imaging milestones, strategic transactions and quarterly performance updates that shape Philips’ role in global health technology.
Royal Philips (NYSE: PHG) announced the next-generation Azurion image-guided therapy platform, enhancing clinical and operational lab performance. This platform integrates imaging, physiology, hemodynamic, and informatics applications for improved clinician control during procedures. It features SmartCT, allowing 3D CT-like image acquisition and visualization. With over two million procedures performed since its launch, Azurion helps streamline workflows, improve decision-making, and optimize patient care. The platform is available in three versions, catering to specific customer needs.
Royal Philips (NYSE: PHG) announced a partial termination of its ventilator contract with the U.S. Department of Health and Human Services (HHS), reducing the original order of 43,000 ventilators by 30,700 units. Philips has successfully delivered 12,300 ventilator configurations to the Strategic National Stockpile by the end of August 2020. CEO Frans van Houten stated that while the reduction will impact financial performance, the company expects to achieve modest sales growth and an Adjusted EBITA margin comparable to last year by year's end.
Philips has launched the Affiniti CVx and released version 7.0 of its EPIQ CVx ultrasound systems at ESC 2020. These advancements aim to enhance productivity in cardiology departments amid rising patient volumes linked to cardiac diseases. Key features include a streamlined workflow for cardiologists, AutoStrain technology that delivers a 70% reduction in analysis time, and various automated tools for improved diagnostic confidence. The Affiniti CVx has not yet received a CE mark for EU marketing.
Royal Philips (NYSE: PHG) is showcasing its latest cardiac care innovations at the ESC Congress 2020, emphasizing integrated solutions that enhance clinical confidence and improve patient outcomes. Key highlights include the launch of the Affiniti CVx ultrasound solution and enhancements to the EPIQ CVx. Philips' offerings aim to facilitate value-based care amidst the COVID-19 pandemic, aiding healthcare providers in balancing quality and cost. The event runs from August 29 to September 1, focusing on the importance of informed decision-making through advanced informatics.
Royal Philips (NYSE: PHG) announced enhancements to its KODEX-EPD cardiac imaging system, aimed at improving cryoablation procedures for patients with Atrial Fibrillation (AF). The system is now operational at 40 sites worldwide, having treated over 1500 patients. Key improvements include faster, high-resolution imaging, enhanced mapping functionality, and new visualization options. The KODEX-EPD system allows for quicker, radiation-free imaging, which could lead to better patient outcomes and more efficient workflows for healthcare providers.
Royal Philips (NYSE: PHG) and B. Braun Medical Inc. received FDA clearance for Onvision®, an innovative ultrasound guidance solution for real-time needle tip tracking in regional anesthesia. This technology aims to enhance accuracy in Peripheral Nerve Blocks (PNBs), potentially reducing the inefficacy rate of such procedures, currently estimated at 10-15%. The Onvision system, integrated with the Xperius® ultrasound system, offers anesthesiologists increased confidence and efficiency during procedures. The solution is expected to be available in the U.S. by Q4 2020, complementing its existing CE mark for the EU and Chile.
Royal Philips (NYSE: PHG) and B. Braun have received FDA 510(k) clearance for Onvision, an advanced ultrasound guidance solution designed for real-time needle tip tracking during peripheral nerve blocks. This technology addresses the critical challenge of accurate needle placement, which is essential for successful regional anesthesia. Onvision is anticipated to enhance procedural efficiency and increase the confidence of anesthesiologists. This innovative product also boasts CE marking and is expected to be available in the U.S. by Q4 2020.
Royal Philips launched its Rapid Equipment Deployment Kit, aimed at enhancing critical care patient monitoring amidst the COVID-19 pandemic. This innovative solution allows hospitals to swiftly scale ICU capabilities, providing 20 monitors and necessary equipment to transform general care areas into critical care units within hours. The kits, currently in use across the U.S., also help manage surges in healthcare demand during natural disasters and health crises. Philips emphasizes efficiency and rapid deployment to support healthcare workers in urgent situations.
Royal Philips (NYSE: PHG) launched the Virtual Care Station, a telehealth solution enabling access to clinicians in community locations like retail settings and libraries. Designed to mitigate barriers to telehealth, it offers local, face-to-face virtual care, particularly in underserved areas. This initiative aligns with the Quadruple Aim, aiming to enhance clinical outcomes, reduce costs, and improve satisfaction. The station is tailored for various needs, including wheelchair accessibility, and has potential future applications like tele-dentistry. Philips aims to alleviate pressure on overburdened healthcare systems during the COVID-19 pandemic.